Johansson, Peter A.
Brooks, Kelly
Newell, Felicity
Palmer, Jane M. http://orcid.org/0000-0002-2702-522X
Wilmott, James S.
Pritchard, Antonia L.
Broit, Natasa
Wood, Scott
Carlino, Matteo S.
Leonard, Conrad
Koufariotis, Lambros T.
Nathan, Vaishnavi http://orcid.org/0000-0001-7201-6819
Beasley, Aaron B. http://orcid.org/0000-0001-5727-7463
Howlie, Madeleine
Dawson, Rebecca
Rizos, Helen http://orcid.org/0000-0002-2094-9198
Schmidt, Chris W. http://orcid.org/0000-0002-3955-5076
Long, Georgina V.
Hamilton, Hayley
Kiilgaard, Jens F. http://orcid.org/0000-0003-1054-1460
Isaacs, Timothy
Gray, Elin S. http://orcid.org/0000-0002-8613-3570
Rolfe, Olivia J.
Park, John J.
Stark, Andrew
Mann, Graham J.
Scolyer, Richard A. http://orcid.org/0000-0002-8991-0013
Pearson, John V.
van Baren, Nicolas
Waddell, Nicola http://orcid.org/0000-0002-3950-2476
Wadt, Karin W. http://orcid.org/0000-0003-2882-6798
McGrath, Lindsay A. http://orcid.org/0000-0003-0925-1124
Warrier, Sunil K.
Glasson, William
Hayward, Nicholas K. http://orcid.org/0000-0003-4760-1033
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1093017, 1111678, 1139071)
Article History
Received: 2 December 2019
Accepted: 22 April 2020
First Online: 15 May 2020
Competing interests
: J.V.P. and N.W. are founders and shareholders of genomiQa Pty Ltd, and members of its Board. K.W.W. participated in one Advisory board meeting for MSD and AstraZeneca. R.A.S. receives fees for professional services from Merck Sharp & Dohme, GlaxoSmithKline Australia, Bristol-Myers Squibb, Dermpedia, Novartis Pharmaceuticals Australia Pty Ltd, Myriad, NeraCare and Amgen. G.V.L. is consulant advisor for Aduro, Amgen, Array, BMS, MERCK MSD, Novartis, Pierre-Fabre, Roche. None of these relationships involve the work described in this manuscript. The remaining authors declare no competing interests.